Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-palmitoyl-2-lysophosphatidylcholine + palmitoyl-CoA
1,2-dipalmitoylphosphatidylcholine + CoA
activity observed only in the presence of phosphatidylcholine (1 mg/ml)
-
-
?
1-palmitoyl-2-lysophosphatidylglycerol + palmitoyl-CoA
1,2-dipalmitoylphosphatidylglycerol + CoA
activity observed only in the presence of phosphatidylcholine (1 mg/ml)
-
-
?
acyl-CoA + 1-acyl-sn-lysophosphatidylcholine
CoA + 1,2-diacyl-sn-lysophosphatidylcholine
-
-
-
?
linoleoyl-CoA + 1-palmitoyl-2-lysophosphatidylcholine
CoA + 1-palmitoyl-2-linoleoylphosphatidylcholine
-
-
-
?
lyso-platelet-activating factor + acetyl-CoA
platelet-activating factor + CoA
activity observed only in the presence of phosphatidylcholine (1 mg/ml)
-
-
?
lysophosphatidylcholine + acyl-CoA
phosphatidylcholine + CoA
-
-
-
?
palmitoyl-CoA + 1-palmitoyl-2-lysophosphatidylcholine
CoA + 1,2-dipalmitoylphosphatidylcholine
-
-
-
?
palmitoyl-CoA + 1-palmitoyl-lysophosphatidylcholine
CoA + 1,2-dipalmitoyl-lysophosphatidylcholine
quantification of palmitic acid by gas chromatography
-
-
?
palmitoyl-CoA + 1-palmitoyl-sn-lysophosphatidylcholine
CoA + 1,2-dipalmitoyl-sn-lysophosphatidylcholine
-
-
-
?
palmitoyl-CoA + 2-palmitoyl-lysophosphatidylcholine
CoA + 1,2-dipalmitoyl-sn-lysophosphatidylcholine
reaction of EC 2.3.1.62
-
-
?
1-acyl-2-lysophosphatidylethanolamine + oleoyl-CoA
1-acyl-2-oleoylphosphatidylethanolamine + CoA
-
-
-
?
1-myristoyl-lysophosphatidylcholine + palmitoyl-CoA
CoA + 1-myristoyl-2-palmitoylphosphatidylcholine
-
-
-
-
?
1-oleoyl-lysophosphatidylcholine + palmitoyl-CoA
CoA + 1-oleoyl-2-palmitoylphosphatidylcholine
-
-
-
-
?
1-palmitoyl-2-lysophosphatidylcholine + alpha-linolenoyl-CoA
1-palmitoyl-2-alpha-linolenoylphosphatidylcholine + CoA
-
-
-
?
1-palmitoyl-2-lysophosphatidylcholine + arachidonoyl-CoA
1-palmitoyl-2-arachidonoylphosphatidylcholine + CoA
1-palmitoyl-2-lysophosphatidylcholine + linoleoyl-CoA
1-palmitoyl-2-linoleoylphosphatidylcholine + CoA
-
-
-
?
1-palmitoyl-2-lysophosphatidylcholine + oleoyl-CoA
1-palmitoyl-2-oleoylphosphatidylcholine + CoA
-
-
-
?
1-palmitoyl-2-lysophosphatidylcholine + stearoyl-CoA
1-palmitoyl-2-stearoylphosphatidylcholine + CoA
-
-
-
?
1-palmitoyl-2-lysophosphatidylserine + arachidonoyl-CoA
1-palmitoyl-2-arachidonoylphosphatidylserine + CoA
-
-
-
?
1-palmitoyl-2-lysophosphatidylserine + linoleoyl-CoA
1-palmitoyl-2-linoleoylphosphatidylserine + CoA
-
-
-
?
1-palmitoyl-lysophosphatidylcholine + arachidonoyl-CoA
CoA + 1-palmitoyl-2-arachidonoylphosphatidylcholine
-
-
-
-
?
1-palmitoyl-lysophosphatidylcholine + lauroyl-CoA
CoA + 1-palmitoyl-2-lauroylphosphatidylcholine
-
-
-
-
?
1-palmitoyl-lysophosphatidylcholine + linoleoyl-CoA
CoA + 1-palmitoyl-2-linoleoylphosphatidylcholine
-
-
-
-
?
1-palmitoyl-lysophosphatidylcholine + n-octanoyl-CoA
CoA + 1-palmitoyl-2-octanoylphosphatidylcholine
-
-
-
-
?
1-palmitoyl-lysophosphatidylcholine + oleoyl-CoA
CoA + 2-oleoyl-1-palmitoylphosphatidylcholine
-
-
-
-
?
1-palmitoyl-lysophosphatidylcholine + palmitoyl-CoA
CoA + 1,2-dipalmitoylphosphatidylcholine
-
-
-
-
?
1-palmitoyl-lysophosphatidylcholine + stearoyl-CoA
CoA + 1-palmitoyl-2-stearoylphosphatidylcholine
-
-
-
-
?
1-stearoyl-lysophosphatidylcholine + palmitoyl-CoA
CoA + 1-stearoyl-2-palmitoylphosphatidylcholine
-
-
-
-
?
acyl-CoA + 1-acyl-2-lysophosphatidylethanolamine
1,2-diacylphosphatidylethanolamine + CoA
-
-
-
?
acyl-CoA + 1-acyl-sn-glycero-3-phosphocholine
CoA + 1,2-diacyl-sn-glycero-3-phosphocholine
arachidonoyl-CoA + 1-acyl-sn-glycero-3-phosphocholine
CoA + 1-acyl-2-arachidonoyl-sn-glycero-3-phosphocholine
-
-
-
?
arachidonoyl-CoA + 1-arachidoyl-2-lysophosphatidylcholine
CoA + 2-arachidonoyl-1-arachidoylphosphatidylcholine
-
-
-
?
arachidonoyl-CoA + 1-O-hexadecyl-sn-glycero-3-phosphocholine
CoA + 2-arachidonoyl-1-O-hexadecyl-sn-glycero-3-phosphocholine
LPCAT3 acylates 1-O-alkyl-sn-glycero-3-phosphocholine with arachidonyl-CoA but not with acetyl-CoA
-
-
?
arachidonoyl-CoA + 1-palmitoyl-2-lysophosphatidylcholine
CoA + 2-arachidonoyl-1-palmitoylphosphatidylcholine
-
-
-
?
arachidonoyl-CoA + 1-palmitoyl-2-lysophosphatidylethanolamine
CoA + 2-arachidonoyl-1-palmitoylphosphatidylethanolamine
lysophosphatidylethanolamine acylation is evident. But no significant activity of acylation is detected when 16:0-lysophosphatidylglycerol is used as substrate
-
-
?
arachidonoyl-CoA + 1-stearoyl-2-lysophosphatidylcholine
CoA + 2-arachidonoyl-1-stearoylphosphatidylcholine
-
-
-
?
arachidonoyl-CoA + NBD-labelled lysophosphatidylcholine
CoA + NBD-2-arachidonoyl-phosphatidylcholine
-
-
-
-
arachidonoyl-CoA + palmitoyl-lysophosphatidylcholine
CoA + 2-arachidonoyl-1-palmitoylphosphatidylcholine
-
-
-
?
linoleoyl-CoA + 1-acyl-sn-glycero-3-phosphocholine
CoA + 1-acyl-2-linoleoyl-sn-glycero-3-phosphocholine
-
-
-
?
linoleoyl-CoA + 1-palmitoyl-2-lysophosphatidylcholine
CoA + 2-linoleoyl-1-palmitoylphosphatidylcholine
-
-
-
?
lysophosphatidylcholine + acyl-CoA
phosphatidylcholine + CoA
-
-
-
?
oleoyl-CoA + 1-palmitoyl-2-lysophosphatidylcholine
CoA + 2-oleoyl-1-palmitoylphosphatidylcholine
-
-
-
?
oleoyl-CoA + 1-palmitoyl-sn-glycero-3-phosphocholine
CoA + 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
-
-
-
-
?
oleoyl-CoA + palmitoyl-lysophosphatidylcholine
CoA + 2-oleoyl-1-palmitoylphosphatidylcholine
-
-
-
?
oleoyl-CoA + sn-1-myristoyl-lysophosphatidylcholine
CoA + 1-myristoyl-2-oleoylphosphatidylcholine
-
-
-
-
?
oleoyl-CoA + sn-1-oleoyl-lysophosphatidylcholine
CoA + 1,2-dioleoylphosphatidylcholine
-
-
-
-
?
oleoyl-CoA + sn-1-stearoyl-lysophosphatidylcholine
CoA + 2-oleoyl-1-stearoylphosphatidylcholine
-
-
-
-
?
palmitoyl-CoA + 1-palmitoyl-2-lysophosphatidylcholine
CoA + 1,2-dipalmitoylphosphatidylcholine
-
-
-
?
palmitoyl-CoA + 1-palmitoyl-sn-glycero-3-phosphocholine
CoA + 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
palmitoyl-CoA + 1-palmitoyl-sn-glycero-3-phosphocholine
CoA + 1,2-dipalmitoylphosphatidylcholine
-
-
-
-
?
palmitoyl-CoA + sn-1-myristoyl-lysophosphatidylcholine
CoA + 1-myristoyl-2-palmitoylphosphatidylcholine
-
-
-
-
?
palmitoyl-CoA + sn-1-oleoyl-lysophosphatidylcholine
CoA + 1-oleoyl-2-palmitoylphosphatidylcholine
-
-
-
-
?
palmitoyl-CoA + sn-1-stearoyl-lysophosphatidylcholine
CoA + 1-stearoyl-2-palmitoylphosphatidylcholine
-
-
-
-
?
stearoyl-CoA + 1-palmitoyl-2-lysophosphatidylcholine
CoA + 2-stearoyl-1-palmitoylphosphatidylcholine
-
-
-
?
stearoyl-CoA + 1-palmitoyl-sn-glycero-3-phosphocholine
CoA + 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine
-
-
-
-
?
additional information
?
-
1-palmitoyl-2-lysophosphatidylcholine + arachidonoyl-CoA
1-palmitoyl-2-arachidonoylphosphatidylcholine + CoA
-
-
-
?
1-palmitoyl-2-lysophosphatidylcholine + arachidonoyl-CoA
1-palmitoyl-2-arachidonoylphosphatidylcholine + CoA
-
-
-
-
?
acyl-CoA + 1-acyl-sn-glycero-3-phosphocholine
CoA + 1,2-diacyl-sn-glycero-3-phosphocholine
-
-
-
r
acyl-CoA + 1-acyl-sn-glycero-3-phosphocholine
CoA + 1,2-diacyl-sn-glycero-3-phosphocholine
-
-
-
r
acyl-CoA + 1-acyl-sn-glycero-3-phosphocholine
CoA + 1,2-diacyl-sn-glycero-3-phosphocholine
-
-
-
?
palmitoyl-CoA + 1-palmitoyl-sn-glycero-3-phosphocholine
CoA + 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
-
-
-
?
palmitoyl-CoA + 1-palmitoyl-sn-glycero-3-phosphocholine
CoA + 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
quantification of palmitic acid by gas chromatography
-
-
?
additional information
?
-
development and evaluation of an accurate and versatile method for determining the acyl group-introducing position of lysophospholipid acyltransferases, overview. Positional specificity of the hydroxyl group of the glycerol backbone (sn-2 or sn-1) at which LPLATs introduce a fatty acid. LPCAT1 introduces palmitic acid both at the sn-1 and sn-2 positions of palmitoyl-lysophosphatidylcholine (LPC). sn-1-Palmitoyl LPC appears to have a slightly higher affinity for LPCAT1 than sn-2-palmitoyl LPC, while sn-2-palmitoyl LPC has a higher turnover rate
-
-
-
additional information
?
-
-
priming of Mono-Mac 6 cells by IFNgamma appears to involve LPCAT
-
-
?
additional information
?
-
-
the enzyme may mediate the priming reactions of monocytes to the cytokine interferon-gamma. The enzyme might also effect the responses of monocytes to the bacterial agent lipopolysaccharide that may be important in the development of sepsis
-
-
?
additional information
?
-
-
low activity with lauroyl-CoA, linoleoyl-CoA and arachidonyl-CoA
-
-
?
additional information
?
-
-
inhibition of Golgi complex-associated LPAT activity by the drug CI-976 stimulates Golgi tubule formation and subsequent redistribution of resident Golgi proteins to the endoplasmic reticulum, affecting secretory and endocytic membrane trafficking pathways, overview
-
-
?
additional information
?
-
reduced activity with lysophosphatidylethanolamine and lysophosphatidylserine
-
-
?
additional information
?
-
-
reduced activity with lysophosphatidylethanolamine and lysophosphatidylserine
-
-
?
additional information
?
-
a linear incorporation of labeled fatty acyl CoA into dipalmitoyl phosphatidylcholine (PC) indicates that lysophosphatidylcholine generated by Prdx6 PLA2 activity remains bound to the enzyme for the reacylation reaction
-
-
-
additional information
?
-
the enzyme is highly specific for substrates palmitoyl-CoA and lysophosphatidylcholine. Lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidylinositol, and lysophosphatidylserine are poor substrates, as well as stearoyl-CoA, acetyl-CoA, oleoyl-CA, and arachidonoyl-CoA
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-acylglycerophosphocholine o-acyltransferase deficiency
Ablation of ALCAT1 Mitigates Hypertrophic Cardiomyopathy through Effects on Oxidative Stress and Mitophagy.
1-acylglycerophosphocholine o-acyltransferase deficiency
ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis.
1-acylglycerophosphocholine o-acyltransferase deficiency
Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson's diseases.
1-acylglycerophosphocholine o-acyltransferase deficiency
Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity.
1-acylglycerophosphocholine o-acyltransferase deficiency
Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet.
1-acylglycerophosphocholine o-acyltransferase deficiency
ER phospholipid composition modulates lipogenesis during feeding and in obesity.
1-acylglycerophosphocholine o-acyltransferase deficiency
LPCAT3 deficiency in hematopoietic cells alters cholesterol and phospholipid homeostasis and promotes atherosclerosis.
1-acylglycerophosphocholine o-acyltransferase deficiency
Lysophosphatidylcholine acyltransferase 3 deficiency impairs 3T3L1 cell adipogenesis through activating Wnt/?-catenin pathway.
1-acylglycerophosphocholine o-acyltransferase deficiency
Macrophage Lysophosphatidylcholine Acyltransferase 3 Deficiency-Mediated Inflammation Is Not Sufficient to Induce Atherosclerosis in a Mouse Model.
1-acylglycerophosphocholine o-acyltransferase deficiency
Metabolic interactions between the Lands cycle and the Kennedy pathway of glycerolipid synthesis in Arabidopsis developing seeds.
1-acylglycerophosphocholine o-acyltransferase deficiency
Small Intestine but Not Liver Lysophosphatidylcholine Acyltransferase 3 (Lpcat3) Deficiency Has a Dominant Effect on Plasma Lipid Metabolism.
Abetalipoproteinemia
Molecular species of phosphatidylcholine in abetalipoproteinemia: effect of lecithin:cholesterol acyltransferase and lysolecithin acyltransferase.
Acute Lung Injury
Adenovector-mediated gene transfer of lysophosphatidylcholine acyltransferase 1 attenuates oleic acid-induced acute lung injury in rats.
Adenocarcinoma
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer.
Adenoma
Transmembrane orientation of palmitoyl-CoA: lysophosphatidylcholine acyltransferase in microsomes isolated from an alveolar type II cell adenoma and rat liver.
Asthma
Lyso-PAF acetyltransferase activity in neutrophils of patients during acute asthma and after recovery.
Atherosclerosis
A novel assay for measuring recombinant human lysophosphatidylcholine acyltransferase 3 activity.
Atherosclerosis
Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet.
Atherosclerosis
LPCAT3 deficiency in hematopoietic cells alters cholesterol and phospholipid homeostasis and promotes atherosclerosis.
Atherosclerosis
Lysophosphatidylcholine Acyltransferase-3 Expression Is Associated with Atherosclerosis Progression.
Atherosclerosis
Macrophage Lysophosphatidylcholine Acyltransferase 3 Deficiency-Mediated Inflammation Is Not Sufficient to Induce Atherosclerosis in a Mouse Model.
Atherosclerosis
Phospholipid Remodeling in Physiology and Disease.
Breast Neoplasms
Expression and clinicopathological significance of AOC4P, PRNCR1, and PCAT1 lncRNAs in breast cancer.
Breast Neoplasms
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.
Breast Neoplasms
Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer.
Carcinogenesis
Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients.
Carcinogenesis
LncRNA PCAT1 promotes metastasis of endometrial carcinoma through epigenetical downregulation of E-cadherin associated with methyltransferase EZH2.
Carcinogenesis
The role of the small intestine in modulating metabolism and inflammation in atherosclerosis and cancer.
Carcinoma
A novel assay for measuring recombinant human lysophosphatidylcholine acyltransferase 3 activity.
Carcinoma
Differential lysophosphatidylcholine acyltransferase 1 (LPCAT1) expression confers aggressiveness and independently predicts recurrence in bladder urothelial carcinomas.
Carcinoma
Long non-coding RNA PCAT1 drives clear cell renal cell carcinoma by upregulating YAP via sponging miR-656 and miR-539.
Carcinoma
Long noncoding RNA PCAT1, a novel serum-based biomarker, enhances cell growth by sponging miR-326 in oesophageal squamous cell carcinoma.
Carcinoma
LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma.
Carcinoma
Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.
Carcinoma, Hepatocellular
Identification and characterization of a major liver lysophosphatidylcholine acyltransferase.
Carcinoma, Hepatocellular
LncRNA PCAT1 enhances cell proliferation, migration and invasion by miR-508-3p/NFIB axis in diffuse large B-cell lymphoma.
Carcinoma, Hepatocellular
Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression.
Carcinoma, Hepatocellular
Regulation of LPCAT3 by LXR.
Carcinoma, Hepatocellular
TGF-?-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury.
Carcinoma, Non-Small-Cell Lung
GATA6 activated long non-coding RNA PCAT1 maintains stemness of non-small cell lung cancer by mediating FRK.
Carcinoma, Renal Cell
Long non-coding RNA PCAT1 drives clear cell renal cell carcinoma by upregulating YAP via sponging miR-656 and miR-539.
Carcinoma, Renal Cell
Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.
Cardiomyopathies
Ablation of ALCAT1 Mitigates Hypertrophic Cardiomyopathy through Effects on Oxidative Stress and Mitophagy.
Cardiomyopathy, Dilated
Cardiolipin remodeling by ALCAT1 links hypoxia to coronary artery disease by promoting mitochondrial dysfunction.
Cardiomyopathy, Hypertrophic
Ablation of ALCAT1 Mitigates Hypertrophic Cardiomyopathy through Effects on Oxidative Stress and Mitophagy.
Cholangiocarcinoma
Long noncoding RNA PCAT1 regulates extrahepatic cholangiocarcinoma progression via the Wnt/?-catenin-signaling pathway.
Cholangiocarcinoma
PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3.
Cholelithiasis
Lysophosphatidylcholine acyltransferase activity during experimental cholelithiasis.
Colorectal Neoplasms
Accumulated phosphatidylcholine (16:0/16:1) in human colorectal cancer; possible involvement of LPCAT4.
Colorectal Neoplasms
lncRNA-PCAT1 rs2632159 polymorphism could be a biomarker for colorectal cancer susceptibility.
Colorectal Neoplasms
LPCAT2 controls chemoresistance in colorectal cancer.
Colorectal Neoplasms
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer.
Colorectal Neoplasms
Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.
Coronary Artery Disease
Cardiolipin remodeling by ALCAT1 links hypoxia to coronary artery disease by promoting mitochondrial dysfunction.
Demyelinating Diseases
Structural specificity in demyelination induced by lysophospholipids.
Endometrial Neoplasms
LncRNA PCAT1 promotes metastasis of endometrial carcinoma through epigenetical downregulation of E-cadherin associated with methyltransferase EZH2.
Endometrial Neoplasms
PCAT1 is a poor prognostic factor in endometrial carcinoma and associated with cancer cell proliferation, migration and invasion.
Endometriosis
SNP rs710886 A>G in long noncoding RNA PCAT1 is associated with the risk of endometriosis by modulating expression of multiple stemness-related genes via microRNA-145 signaling pathway.
Esophageal Neoplasms
Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients.
Esophageal Squamous Cell Carcinoma
Long noncoding RNA PCAT1, a novel serum-based biomarker, enhances cell growth by sponging miR-326 in oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma.
Fatty Liver
A novel assay for measuring recombinant human lysophosphatidylcholine acyltransferase 3 activity.
Fatty Liver
ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis.
Fatty Liver
Caspase-independent hepatocyte death: A result of the decrease of lysophosphatidylcholine acyltransferase 3 in non-alcoholic steatohepatitis.
Glioma
Knockdown of long non-coding RNA PCAT1 in glioma stem cells promotes radiation sensitivity.
Glucose Intolerance
Lysophospholipid acylation modulates plasma membrane lipid organization and insulin sensitivity in skeletal muscle.
Heart Diseases
Ablation of ALCAT1 Mitigates Hypertrophic Cardiomyopathy through Effects on Oxidative Stress and Mitophagy.
Hepatitis C
Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus: impact on production of lipo-viro-particles.
Hepatomegaly
Responses of the liver to perfluorinated fatty acids with different carbon chain length in male and female mice:in relation to induction of hepatomegaly, peroxisomal beta-oxidation and microsomal 1-acylglycerophosphocholine acyltransferase.
Hepatomegaly
Sex-related difference in the inductions by perfluoro-octanoic acid of peroxisomal beta-oxidation, microsomal 1-acylglycerophosphocholine acyltransferase and cytosolic long-chain acyl-CoA hydrolase in rat liver.
Hyperglycemia
Liver-specific overexpression of LPCAT3 reduces postprandial hyperglycemia and improves lipoprotein metabolic profile in mice.
Hyperlipidemias
Deficiency in lysophosphatidylcholine acyltransferase 3 reduces plasma levels of lipids by reducing lipid absorption in mice.
Hyperlipidemias
Small Intestine but Not Liver Lysophosphatidylcholine Acyltransferase 3 (Lpcat3) Deficiency Has a Dominant Effect on Plasma Lipid Metabolism.
Hyperthyroidism
Ablation of ALCAT1 Mitigates Hypertrophic Cardiomyopathy through Effects on Oxidative Stress and Mitophagy.
Hyperthyroidism
Influence of hypo- and hyperthyroidism on rat liver glycerophospholipid metabolism.
Hypothyroidism
ALCAT1 is a polyglycerophospholipid acyltransferase potently regulated by adenine nucleotide and thyroid status.
Hypothyroidism
Influence of hypo- and hyperthyroidism on rat liver glycerophospholipid metabolism.
Infections
Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice.
Infertility
On the Role of DGAT1 in Seed Glycerolipid Metabolic Network and Critical Stages of Plant Development in Arabidopsis.
Influenza, Human
Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice.
Insulin Resistance
Ablation of ALCAT1 Mitigates Hypertrophic Cardiomyopathy through Effects on Oxidative Stress and Mitophagy.
Insulin Resistance
Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity.
Insulin Resistance
ER phospholipid composition modulates lipogenesis during feeding and in obesity.
Insulin Resistance
Lysophospholipid acylation modulates plasma membrane lipid organization and insulin sensitivity in skeletal muscle.
Insulin Resistance
Remodeling glycerophospholipids affects obesity-related insulin signaling in skeletal muscle.
Laryngeal Neoplasms
Long non-coding RNA PCAT1 promotes cell migration and invasion in human laryngeal cancer by sponging miR-210-3p.
Leukemia, Myeloid, Acute
Identification of LPCAT1 expression as a potential prognostic biomarker guiding treatment choice in acute myeloid leukemia.
Liver Diseases
ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis.
Liver Diseases
Phospholipid Remodeling in Physiology and Disease.
Lung Neoplasms
GATA6 activated long non-coding RNA PCAT1 maintains stemness of non-small cell lung cancer by mediating FRK.
Lung Neoplasms
LncRNA PRNCR1 rs1456315 and CCAT2 rs6983267 Polymorphisms on 8q24 Associated with Lung Cancer.
Lung Neoplasms
Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics.
Lymphatic Metastasis
PCAT1 is a poor prognostic factor in endometrial carcinoma and associated with cancer cell proliferation, migration and invasion.
Lymphoma, B-Cell
LncRNA PCAT1 enhances cell proliferation, migration and invasion by miR-508-3p/NFIB axis in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
LncRNA PCAT1 enhances cell proliferation, migration and invasion by miR-508-3p/NFIB axis in diffuse large B-cell lymphoma.
Melanoma
Anti-melanoma activity of Forsythiae Fructus aqueous extract in mice involves regulation of glycerophospholipid metabolisms by UPLC/Q-TOF MS-based metabolomics study.
Melanoma
Simultaneous silencing of lysophosphatidylcholine acyltransferases 1-4 by nucleic acid nanoparticles (NANPs) improves radiation response of melanoma cells.
Muscular Diseases
Low lysophosphatidylcholine induces skeletal muscle myopathy that is aggravated by high-fat diet feeding.
Myocardial Infarction
Aerobic exercise alleviates oxidative stress-induced apoptosis in kidneys of myocardial infarction mice by inhibiting ALCAT1 and activating FNDC5/Irisin signaling pathway.
Myocardial Ischemia
Accumulation of unesterified arachidonic acid in ischemic canine myocardium. Relationship to a phosphatidylcholine deacylation-reacylation cycle and the depletion of membrane phospholipids.
Neoplasm Metastasis
LncRNA PCAT1 enhances cell proliferation, migration and invasion by miR-508-3p/NFIB axis in diffuse large B-cell lymphoma.
Neoplasm Metastasis
LncRNA PCAT1 promotes metastasis of endometrial carcinoma through epigenetical downregulation of E-cadherin associated with methyltransferase EZH2.
Neoplasm Metastasis
Long non-coding RNA PCAT1 promotes cell migration and invasion in human laryngeal cancer by sponging miR-210-3p.
Neoplasm Metastasis
LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Neoplasm Metastasis
PCAT1 is a poor prognostic factor in endometrial carcinoma and associated with cancer cell proliferation, migration and invasion.
Neoplasm Metastasis
The lncRNA PCAT1 is correlated with poor prognosis and promotes cell proliferation, invasion, migration and EMT in osteosarcoma.
Neoplasms
A rare variant of African ancestry activates 8q24 lncRNA hub by modulating cancer associated enhancer.
Neoplasms
Angustoline Inhibited Esophageal Tumors Through Regulating LKB1/AMPK/ELAVL1/LPACT2 Pathway and Phospholipid Remodeling.
Neoplasms
Differential lysophosphatidylcholine acyltransferase 1 (LPCAT1) expression confers aggressiveness and independently predicts recurrence in bladder urothelial carcinomas.
Neoplasms
Expression and clinicopathological significance of AOC4P, PRNCR1, and PCAT1 lncRNAs in breast cancer.
Neoplasms
GATA6 activated long non-coding RNA PCAT1 maintains stemness of non-small cell lung cancer by mediating FRK.
Neoplasms
Genome-wide expression profiling in colorectal cancer focusing on lncRNAs in the adenoma-carcinoma transition.
Neoplasms
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.
Neoplasms
Increased prostatic lysophosphatidylcholine acyltransferase activity in human prostate cancer: a marker for malignancy.
Neoplasms
Knockdown of lncRNA PCAT1 Enhances Radiosensitivity of Cervical Cancer by Regulating miR-128/GOLM1 Axis.
Neoplasms
LncRNA PCAT1 and its genetic variant rs1902432 are associated with prostate cancer risk.
Neoplasms
LncRNA PRNCR1 rs1456315 and CCAT2 rs6983267 Polymorphisms on 8q24 Associated with Lung Cancer.
Neoplasms
lncRNAs in Non-Malignant Tissue Have Prognostic Value in Colorectal Cancer.
Neoplasms
Long non-coding RNA PCAT1 drives clear cell renal cell carcinoma by upregulating YAP via sponging miR-656 and miR-539.
Neoplasms
Long non-coding RNA PCAT1 promotes cell migration and invasion in human laryngeal cancer by sponging miR-210-3p.
Neoplasms
Long noncoding RNA PCAT1, a novel serum-based biomarker, enhances cell growth by sponging miR-326 in oesophageal squamous cell carcinoma.
Neoplasms
LPCAT1 overexpression promotes the progression of hepatocellular carcinoma.
Neoplasms
LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Neoplasms
LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma.
Neoplasms
Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics.
Neoplasms
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.
Neoplasms
MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions.
Neoplasms
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer.
Neoplasms
Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling.
Neoplasms
Palliation of bone cancer pain by antagonists of platelet-activating factor receptors.
Neoplasms
PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3.
Neoplasms
PCAT1 is a poor prognostic factor in endometrial carcinoma and associated with cancer cell proliferation, migration and invasion.
Neoplasms
PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.
Neoplasms
PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer.
Neoplasms
PCAT1: An oncogenic lncRNA in diverse cancers and a putative therapeutic target.
Neoplasms
Phospholipid Remodeling in Physiology and Disease.
Neoplasms
The activities of monocyte lysophosphatidylcholine acyltransferase and coenzyme A-independent transacylase are changed by the inflammatory cytokines tumor necrosis factor alpha and interferon gamma.
Neoplasms
The association of rs710886 in lncRNA PCAT1 with bladder cancer risk in a Chinese population.
Neoplasms
The lncRNA PCAT1 is correlated with poor prognosis and promotes cell proliferation, invasion, migration and EMT in osteosarcoma.
Neoplasms
Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer.
Nephrotic Syndrome
Abnormal acyltransferase activities and accelerated cholesteryl ester transfer in patients with nephrotic syndrome.
Non-alcoholic Fatty Liver Disease
ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis.
Non-alcoholic Fatty Liver Disease
Phospholipid Remodeling in Physiology and Disease.
Obesity
Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity.
Obesity
Remodeling glycerophospholipids affects obesity-related insulin signaling in skeletal muscle.
Obesity
Two-week administration of engineered Escherichia coli establishes persistent resistance to diet-induced obesity even without antibiotic pre-treatment.
Osteosarcoma
The lncRNA PCAT1 is correlated with poor prognosis and promotes cell proliferation, invasion, migration and EMT in osteosarcoma.
Ovarian Neoplasms
PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.
Pancreatic Neoplasms
Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis.
Peritonitis
Alterations of the composition and metabolism of pulmonary surfactant phospholipids induced by experimental peritonitis in rats.
phosphatidylcholine-sterol o-acyltransferase deficiency
Low density lipoprotein-activated lysolecithin acylation by human plasma lecithin-cholesterol acyltransferase. Identity of lysolecithin acyltransferase and lecithin-cholesterol acyltransferase.
Prostatic Hyperplasia
Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
Prostatic Neoplasms
A Prostate Cancer Risk SNP Upregulates the Tumorigenic lncRNA PCAT1.
Prostatic Neoplasms
A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes.
Prostatic Neoplasms
BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer.
Prostatic Neoplasms
Correction: A Systems Genetics Approach Identifies CXCL14, ITGAX, and LPCAT2 as Novel Aggressive Prostate Cancer Susceptibility Genes.
Prostatic Neoplasms
Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
Prostatic Neoplasms
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.
Prostatic Neoplasms
Increased prostatic lysophosphatidylcholine acyltransferase activity in human prostate cancer: a marker for malignancy.
Prostatic Neoplasms
LncRNA PCAT1 activates AKT and NF-?B signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKK? complex.
Prostatic Neoplasms
LncRNA PCAT1 and its genetic variant rs1902432 are associated with prostate cancer risk.
Prostatic Neoplasms
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer.
Prostatic Neoplasms
The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer.
Prostatic Neoplasms
The Role of Long Non-coding RNA Prostate Cancer-Associated Transcript 1 in Prostate Cancer.
Pulmonary Fibrosis
Lysocardiolipin acyltransferase regulates TGF-? mediated lung fibroblast differentiation.
Pulmonary Fibrosis
The mitochondrial cardiolipin remodeling enzyme lysocardiolipin acyltransferase is a novel target in pulmonary fibrosis.
Rectal Neoplasms
lncRNA-PCAT1 rs2632159 polymorphism could be a biomarker for colorectal cancer susceptibility.
Renal Insufficiency, Chronic
Paricalcitol effects on activities and metabolism of Platelet Activating Factor and on inflammatory cytokines in hemodialysis patients.
Retinal Degeneration
AAV-Mediated Lysophosphatidylcholine Acyltransferase 1 (Lpcat1) Gene Replacement Therapy Rescues Retinal Degeneration in rd11 Mice.
Retinal Diseases
Temporal ChIP-on-Chip of RNA-Polymerase-II to detect novel gene activation events during photoreceptor maturation.
Rhinitis, Allergic
LPCAT2 Methylation, a Novel Biomarker for the Severity of Cedar Pollen Allergic Rhinitis in Japan.
Sepsis
Alteration of Lysophosphatidylcholine-Related Metabolic Parameters in the Plasma of Mice with Experimental Sepsis.
Sepsis
Lysophospholipid acyltransferases in monocyte inflammatory responses and sepsis.
Sepsis
Lysophospholipid acyltransferases: novel potential regulators of the inflammatory response and target for new drug discovery.
Starvation
Intestinal Phospholipid Remodeling Is Required for Dietary-Lipid Uptake and Survival on a High-Fat Diet.
Stomach Neoplasms
Association of Genetic Polymorphisms in the LncRNAs with Gastric Cancer Risk in a Chinese Population.
Stomach Neoplasms
Overexpression of Lysophosphatidylcholine Acyltransferase 1 and Concomitant Lipid Alterations in Gastric Cancer.
Urinary Bladder Neoplasms
The association of rs710886 in lncRNA PCAT1 with bladder cancer risk in a Chinese population.
Uterine Cervical Neoplasms
Interplay Between EGFR and the Platelet-Activating Factor/PAF Receptor Signaling Axis Mediates Aggressive Behavior of Cervical Cancer.
Uterine Cervical Neoplasms
Knockdown of lncRNA PCAT1 Enhances Radiosensitivity of Cervical Cancer by Regulating miR-128/GOLM1 Axis.
Virus Diseases
Phospholipid Remodeling in Physiology and Disease.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Gehring, L.; Haase, D.; Habben, K.; Kerkhoff, C.; Meyer, H.H.; Kaever, V.
Synthesis of an unsaturated fatty acid analog (18-(4'-azido-2'-hydroxybenzoylamino)-oleic acid) and its interaction with lysophosphatidylcholine: acyl-CoA-O-acyltransferase
J. Lipid Res.
39
1118-1126
1998
Homo sapiens
brenda
Rusnak, A.; Coghlan, G.; Zelinski, T.; Hatch, G.M.
Incorporation of fatty acids into phosphatidylcholine is reduced during storage of human erythrocytes: evidence for distinct lysophosphatidylcholine acyltransferases
Mol. Cell. Biochem.
213
137-143
2000
Homo sapiens
brenda
Neville, N.T.; Parton, J.; Harwood, J.L.; Jackson, S.K.
The activities of monocyte lysophosphatidylcholine acyltransferase and coenzyme A-independent transacylase are changed by the inflammatory cytokines tumor necrosis factor alpha and interferon gamma
Biochim. Biophys. Acta
1733
232-238
2005
Homo sapiens
brenda
Jackson, S.K.; Parton, J.
Lysophospholipid acyltransferases in monocyte inflammatory responses and sepsis
Immunobiology
209
31-38
2004
Homo sapiens
brenda
Yang, Y.; Cao, J.; Shi, Y.
Identification and characterization of a gene encoding human LPGAT1, an endoplasmic reticulum-associated lysophosphatidylglycerol acyltransferase
J. Biol. Chem.
279
55866-55874
2004
Homo sapiens
brenda
Chambers, K.; Judson, B.; Brown, W.J.
A unique lysophospholipid acyltransferase (LPAT) antagonist, CI-976, affects secretory and endocytic membrane trafficking pathways
J. Cell Sci.
118
3061-3071
2005
Homo sapiens, Rattus norvegicus
brenda
Zhao, Y.; Chen, Y.Q.; Bonacci, T.M.; Bredt, D.S.; Li, S.; Bensch, W.R.; Moller, D.E.; Kowala, M.; Konrad, R.J.; Cao, G.
Identification and characterization of a major liver lysophosphatidylcholine acyltransferase
J. Biol. Chem.
283
8258-8265
2008
Homo sapiens
brenda
Kazachkov, M.; Chen, Q.; Wang, L.; Zou, J.
Substrate preferences of a lysophosphatidylcholine acyltransferase highlight its role in phospholipid remodeling
Lipids
43
895-902
2008
Homo sapiens (Q6P1A2), Homo sapiens
brenda
Matsuda, S.; Inoue, T.; Lee, H.C.; Kono, N.; Tanaka, F.; Gengyo-Ando, K.; Mitani, S.; Arai, H.
Member of the membrane-bound O-acyltransferase (MBOAT) family encodes a lysophospholipid acyltransferase with broad substrate specificity
Genes Cells
13
879-888
2008
Caenorhabditis elegans (O01925), Caenorhabditis elegans, Homo sapiens (Q6P1A2), Homo sapiens
brenda
Cao, J.; Shan, D.; Revett, T.; Li, D.; Wu, L.; Liu, W.; Tobin, J.F.; Gimeno, R.E.
Molecular identification of a novel mammalian brain isoform of acyl-CoA:lysophospholipid acyltransferase with prominent ethanolamine lysophospholipid acylating activity, LPEAT2
J. Biol. Chem.
283
19049-19057
2008
Homo sapiens (Q643R3)
brenda
Gijon, M.A.; Riekhof, W.R.; Zarini, S.; Murphy, R.C.; Voelker, D.R.
Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils
J. Biol. Chem.
283
30235-30245
2008
Homo sapiens (Q6P1A2), Homo sapiens
brenda
Shindou, H.; Shimizu, T.
Acyl-CoA:lysophospholipid acyltransferases
J. Biol. Chem.
284
1-5
2009
Mus musculus (Q3TFD2), Mus musculus (Q8BYI6), Mus musculus (Q8R3I2), Mus musculus (Q91V01), Homo sapiens (Q6P1A2), Homo sapiens (Q6ZWT7), Homo sapiens (Q7L5N7), Homo sapiens (Q8NF37)
brenda
Perez-Chacon, G.; Astudillo, A.M.; Ruiperez, V.; Balboa, M.A.; Balsinde, J.
Signaling role for lysophosphatidylcholine acyltransferase 3 in receptor-regulated arachidonic acid reacylation reactions in human monocytes
J. Immunol.
184
1071-1078
2010
Homo sapiens
brenda
Jain, S.; Zhang, X.; Khandelwal, P.J.; Saunders, A.J.; Cummings, B.S.; Oelkers, P.
Characterization of human lysophospholipid acyltransferase 3
J. Lipid Res.
50
1563-1570
2009
Homo sapiens (Q6P1A2), Homo sapiens
brenda
Harayama, T.; Shindou, H.; Shimizu, T.
Biosynthesis of phosphatidylcholine by human lysophosphatidylcholine acyltransferase 1
J. Lipid Res.
50
1824-1831
2009
Homo sapiens (Q8NF37), Homo sapiens
brenda
Mansilla, F.; da Costa, K.A.; Wang, S.; Kruh?ffer, M.; Lewin, T.M.; Orntoft, T.F.; Coleman, R.A.; Birkenkamp-Demtroeder, K.
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer
J. Mol. Med.
87
85-97
2009
Homo sapiens (Q8NF37), Homo sapiens
brenda
Jackson, S.K.; Abate, W.; Tonks, A.J.
Lysophospholipid acyltransferases: novel potential regulators of the inflammatory response and target for new drug discovery
Pharmacol. Ther.
119
104-114
2008
Bos taurus, Rattus norvegicus, Mus musculus (Q3TFD2), Homo sapiens (Q8NF37)
brenda
Moessinger, C.; Kuerschner, L.; Spandl, J.; Shevchenko, A.; Thiele, C.
Human lysophosphatidylcholine acyltransferases 1 and 2 are located in lipid droplets where they catalyze the formation of phosphatidylcholine
J. Biol. Chem.
286
21330-21339
2011
Homo sapiens (Q7L5N7), Homo sapiens (Q8NF37), Homo sapiens
brenda
Ishibashi, M.; Varin, A.; Filomenko, R.; Lopez, T.; Athias, A.; Gambert, P.; Blache, D.; Thomas, C.; Gautier, T.; Lagrost, L.; Masson, D.
Liver X receptor regulates arachidonic acid distribution and eicosanoid release in human macrophages: a key role for lysophosphatidylcholine acyltransferase 3
Arterioscler. Thromb. Vasc. Biol.
33
1171-1179
2013
Homo sapiens (Q6P1A2), Homo sapiens
brenda
Taniguchi, K.; Hikiji, H.; Okinaga, T.; Hashidate-Yoshida, T.; Shindou, H.; Ariyoshi, W.; Shimizu, T.; Tominaga, K.; Nishihara, T.
Essential role of lysophosphatidylcholine acyltransferase 3 in the induction of macrophage polarization in PMA-treated U937 cells
J. Cell. Biochem.
116
2840-2848
2015
Homo sapiens (Q6P1A2)
brenda
Kawana, H.; Kano, K.; Shindou, H.; Inoue, A.; Shimizu, T.; Aoki, J.
An accurate and versatile method for determining the acyl group-introducing position of lysophospholipid acyltransferases
Biochim. Biophys. Acta
1864
1053-1060
2019
Mus musculus (Q3TFD2), Mus musculus (Q3UN02), Mus musculus (Q91V01), Homo sapiens (Q8NF37)
brenda
Akagi, S.; Kono, N.; Ariyama, H.; Shindou, H.; Shimizu, T.; Arai, H.
Lysophosphatidylcholine acyltransferase 1 protects against cytotoxicity induced by polyunsaturated fatty acids
FASEB J.
30
2027-2039
2016
Mus musculus (Q3TFD2), Mus musculus, Homo sapiens (Q8NF37)
brenda
Du, X.; Hu, J.; Zhang, Q.; Liu, Q.; Xiang, X.; Dong, J.; Lou, B.; He, S.; Gu, X.; Cao, Y.; Li, Y.; Ding, T.
A novel assay for measuring recombinant human lysophosphatidylcholine acyltransferase 3 activity
FEBS open bio
9
1734-1743
2019
Homo sapiens (Q6P1A2), Homo sapiens
brenda
Beilstein, F.; Lemasson, M.; Pene, V.; Rainteau, D.; Demignot, S.; Rosenberg, A.R.
Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus impact on production of lipo-viro-particles
Gut
66
2160-2169
2017
Homo sapiens (Q8NF37), Homo sapiens
brenda
Singh, A.B.; Liu, J.
Identification of hepatic lysophosphatidylcholine acyltransferase 3 as a novel target gene regulated by peroxisome proliferator-activated receptor delta
J. Biol. Chem.
292
884-897
2017
Homo sapiens (Q6P1A2), Mus musculus (Q91V01), Mus musculus
brenda
Fisher, A.B.; Dodia, C.; Sorokina, E.M.; Li, H.; Zhou, S.; Raabe, T.; Feinstein, S.I.
A novel lysophosphatidylcholine acyl transferase activity is expressed by peroxiredoxin 6
J. Lipid Res.
57
587-596
2016
Mus musculus (O08709), Mus musculus, Rattus norvegicus (O35244), Homo sapiens (P30041), Mus musculus C57BL/6J (O08709)
brenda